Inclusion Criteria:  Newly diagnosed breast cancer; 18-75 Years, female; ECOG Performance Status of 0-1; Life expectancy is not less than 3 months; Histologically documented TNBC (negative human epidermal growth factor receptor 2 [HER2], estrogen receptor [ER], and progesterone receptor [PgR] status); Tumor stage: II-III; At least one measurable lesion according to RECIST 1.1; Adequate hematologic and organ function.; Must be willing to use an adequate method of contraception for the course of the study.  Exclusion Criteria:  Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer; Inflammatory breast cancer; Has received prior any anti-tumor therapy within the past 12 months prior to signing informed consent, including chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TACE; Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4]; Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer; Major surgical procedure within 4 weeks prior to initiation of study treatment; Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus; Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases; Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study; Has a known history of Human Immunodeficiency Virus (HIV); Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis; Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia; Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment; Has evidence of active tuberculosis within 1year prior to initiation of study treatment; Prior allogeneic stem cell or solid organ transplantation; Pre-existing motor or sensory neuropathy of a severity≥grade 2; Has significant cardiovascular disease; Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial; History of neurological or psychiatric disorders, including epilepsy or dementia; Any other situation evaluated by researchers.